Literature DB >> 16552415

The therapeutic potential of monoamine oxidase inhibitors.

Moussa B H Youdim1, Dale Edmondson, Keith F Tipton.   

Abstract

Monoamine oxidase inhibitors were among the first antidepressants to be discovered and have long been used as such. It now seems that many of these agents might have therapeutic value in several common neurodegenerative conditions, independently of their inhibition of monoamine oxidase activity. However, many claims and some counter-claims have been made about the physiological importance of these enzymes and the potential of their inhibitors. We evaluate these arguments in the light of what we know, and still have to learn, of the structure, function and genetics of the monoamine oxidases and the disparate actions of their inhibitors.

Mesh:

Substances:

Year:  2006        PMID: 16552415     DOI: 10.1038/nrn1883

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  279 in total

1.  Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease.

Authors:  Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurochem Res       Date:  2010-10-28       Impact factor: 3.996

Review 2.  Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury.

Authors:  Nina Kaludercic; Andrea Carpi; Roberta Menabò; Fabio Di Lisa; Nazareno Paolocci
Journal:  Biochim Biophys Acta       Date:  2010-09-24

3.  Role of reactive oxygen species in hyperadrenergic hypertension: biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin a (Chga) gene.

Authors:  Jiaur R Gayen; Kuixing Zhang; Satish P RamachandraRao; Manjula Mahata; Yuqing Chen; Hyung-Suk Kim; Robert K Naviaux; Kumar Sharma; Sushil K Mahata; Daniel T O'Connor
Journal:  Circ Cardiovasc Genet       Date:  2010-08-20

4.  Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.

Authors:  Claudia Binda; Milagros Aldeco; Werner J Geldenhuys; Marcello Tortorici; Andrea Mattevi; Dale E Edmondson
Journal:  ACS Med Chem Lett       Date:  2011-10-15       Impact factor: 4.345

5.  Tetrahydrobiopterin regulates monoamine neurotransmitter sulfonation.

Authors:  Ian Cook; Ting Wang; Thomas S Leyh
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

6.  Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge.

Authors:  Landhing M Moran; Michael Y Aksenov; Rosemarie M Booze; Katy M Webb; Charles F Mactutus
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

7.  Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition.

Authors:  Erin M MacKenzie; Suzanne L Grant; Glen B Baker; Paul L Wood
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

8.  Synthesis, molecular modeling, and in vitro screening of monoamine oxidase inhibitory activities of some novel hydrazone derivatives.

Authors:  Umut Salgin-Gökşen; Nesrin Gökhan-Kelekçi; Samiye Yabanoglu-Çiftci; Kemal Yelekçi; Gülberk Uçar
Journal:  J Neural Transm (Vienna)       Date:  2013-01-18       Impact factor: 3.575

Review 9.  Selective MAO-B inhibitors: a lesson from natural products.

Authors:  Simone Carradori; Melissa D'Ascenzio; Paola Chimenti; Daniela Secci; Adriana Bolasco
Journal:  Mol Divers       Date:  2013-11-12       Impact factor: 2.943

10.  Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts.

Authors:  Nina Kaludercic; Andrea Carpi; Takahiro Nagayama; Vidhya Sivakumaran; Guangshuo Zhu; Edwin W Lai; Djahida Bedja; Agnese De Mario; Kevin Chen; Kathleen L Gabrielson; Merry L Lindsey; Karel Pacak; Eiki Takimoto; Jean C Shih; David A Kass; Fabio Di Lisa; Nazareno Paolocci
Journal:  Antioxid Redox Signal       Date:  2013-05-22       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.